Effect of Vitamin D Repletion on Insulin Resistance and Systemic Inflammation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01354964|
Recruitment Status : Unknown
Verified May 2011 by Albert Einstein College of Medicine, Inc..
Recruitment status was: Recruiting
First Posted : May 17, 2011
Last Update Posted : May 17, 2011
|Condition or disease||Intervention/treatment||Phase|
|Insulin Resistance||Drug: Vitamin D||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||25 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effect of Vitamin D Repletion on Insulin Resistance and Systemic Inflammation|
|Study Start Date :||March 2009|
|Estimated Primary Completion Date :||March 2015|
|Estimated Study Completion Date :||March 2015|
Experimental: Vitamin D
Drug: Vitamin D
Weekly oral vitamin D drops, weight-based calculated dosage, taken on the same day each week for 4 months.
- Hepatic insulin sensitivity [ Time Frame: 2 and 4 months ]We will examine endogenous glucose production to assess hepatic insulin sensitivity.
- Peripheral insulin sensitivity [ Time Frame: 2 and 4 months ]We will examine the rate of glucose uptake to determine peripheral inslin sensitivity.
- Adipose tissue inflammatory markers/Cytokines in plasma [ Time Frame: 2 and 4 months ]Inflammatory markers-PAI-1, IL-6, TNF-a, iNOS
- Neuropsychological Testing [ Time Frame: 4 months ]We will conduct neuropsychological testing to assess cognitive function.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01354964
|Contact: Stephanie M Lawrence, BSemail@example.com|
|United States, New York|
|Albert Einstein College of Medicine of Yeshiva University||Recruiting|
|Bronx, New York, United States, 10461|
|Contact: Stephanie Lawrence, BS 718-430-2903 firstname.lastname@example.org|
|Principal Investigator: Preeti Kishore, MD|
|Principal Investigator:||Preeti Kishore, MD||Albert Einstein College of Medicine, Inc.|